Physician profile
Aaron Milstone
NPI 1134211550
$482,423.34
in general payments reported to CMS, 2019-2025
52 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211K · 2020: $116K · 2021: $58K · 2022: $41K · 2023: $17K · 2024: $20K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $11K · Consulting Fee: $11K · Food and Beverage: $2,970 · Education: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $19,802.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,414.20 |
| Honoraria | $10,912.50 |
| Consulting Fee | $10,688.00 |
| Food and Beverage | $2,970.17 |
| Education | $733.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124,948.05 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $110,383.23 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $96,562.47 | 2019-2022 | |
| Genentech USA, INC. | $50,830.39 | 2019-2021 | |
| Insmed, INC. | $38,229.14 | 2019-2025 | Arikayce |
| Mylan INC. | $21,368.13 | 2021-2025 | Yupelri |
| Verona Pharma, INC. | $11,579.99 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $7,956.48 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Grifols USA, LLC | $5,011.59 | 2019-2024 | Prolastin-C Liquid |
| Chiesi USA, INC. | $2,456.85 | 2025 | |
| Ani Pharmaceuticals, INC. | $2,053.66 | 2024-2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $2,022.00 | 2025 | Yupelri |
| Csl Behring | $1,963.29 | 2019-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $1,784.52 | 2019-2021 | |
| Viiv Healthcare Company | $1,600.00 | 2019 |
Show all 48 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Milstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.